Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ALLO NASDAQ:CRMD NASDAQ:EQ NASDAQ:TECX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALLOAllogene Therapeutics$1.74-4.4%$1.99$0.98▼$4.46$628.18M0.469.10 million shs4.86 million shsCRMDCorMedix$7.87-2.2%$8.36$6.13▼$14.96$631.54M1.481.08 million shs625,282 shsEQEquillium$2.49-7.4%$2.75$0.37▼$3.54$170.08M1.771.01 million shs197,944 shsTECXTectonic Therapeutic$30.37-3.9%$31.21$14.39▼$39.53$573.05M3.21215,484 shs99,105 shsThe 10 Best High-Yield Dividend Stocks for 2026Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALLOAllogene Therapeutics-4.40%-2.79%-15.12%-24.68%+4.82%CRMDCorMedix-2.24%-6.53%-6.20%+6.06%-32.27%EQEquillium-7.43%-3.86%-12.63%+15.28%+504.37%TECXTectonic Therapeutic-3.92%-6.84%-1.14%+6.41%+32.50%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALLOAllogene Therapeutics$1.74-4.4%$1.99$0.98▼$4.46$628.18M0.469.10 million shs4.86 million shsCRMDCorMedix$7.87-2.2%$8.36$6.13▼$14.96$631.54M1.481.08 million shs625,282 shsEQEquillium$2.49-7.4%$2.75$0.37▼$3.54$170.08M1.771.01 million shs197,944 shsTECXTectonic Therapeutic$30.37-3.9%$31.21$14.39▼$39.53$573.05M3.21215,484 shs99,105 shsThe 10 Best High-Yield Dividend Stocks for 2026Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALLOAllogene Therapeutics-4.40%-2.79%-15.12%-24.68%+4.82%CRMDCorMedix-2.24%-6.53%-6.20%+6.06%-32.27%EQEquillium-7.43%-3.86%-12.63%+15.28%+504.37%TECXTectonic Therapeutic-3.92%-6.84%-1.14%+6.41%+32.50%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALLOAllogene Therapeutics 2.69Moderate Buy$8.52389.78% UpsideCRMDCorMedix 2.75Moderate Buy$14.8688.78% UpsideEQEquillium 2.82Moderate Buy$7.57204.07% UpsideTECXTectonic Therapeutic 2.75Moderate Buy$79.40161.44% UpsideCurrent Analyst Ratings BreakdownLatest EQ, TECX, ALLO, and CRMD Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/21/2026EQEquillium Clear StrSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy7/20/2026TECXTectonic Therapeutic Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold ➝ Strong Sell7/17/2026TECXTectonic Therapeutic Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)7/13/2026EQEquillium Piper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight7/13/2026EQEquillium Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold ➝ Strong Sell7/7/2026CRMDCorMedix Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$14.00 ➝ $13.006/24/2026EQEquillium Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)5/28/2026EQEquillium Raymond James FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingStrong-Buy$7.005/28/2026EQEquillium Stifel NicolausSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$5.005/28/2026EQEquillium Roth CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$12.005/28/2026EQEquillium Leerink PartnersSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeMarket Perform ➝ Outperform$1.00 ➝ $6.00(Data available from 7/25/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALLOAllogene TherapeuticsN/AN/AN/AN/A$1.30 per shareN/ACRMDCorMedix$311.71M1.98$2.00 per share3.94$5.14 per share1.53EQEquilliumN/AN/AN/AN/A$0.47 per shareN/ATECXTectonic TherapeuticN/AN/AN/AN/A$13.43 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALLOAllogene Therapeutics-$190.89M-$0.77N/AN/AN/AN/A-56.45%-40.36%8/12/2026 (Estimated)CRMDCorMedix$163.05M$2.133.69787.00N/A45.25%45.57%24.76%8/6/2026 (Estimated)EQEquillium-$22.40M-$0.32N/AN/AN/AN/A-61.43%-53.72%8/13/2026 (Estimated)TECXTectonic Therapeutic-$74.15M-$4.46N/AN/AN/AN/A-32.33%-30.92%8/6/2026 (Estimated)Latest EQ, TECX, ALLO, and CRMD EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/13/2026Q2 2026EQEquillium-$0.05N/AN/AN/AN/AN/A8/12/2026Q2 2026ALLOAllogene Therapeutics-$0.16N/AN/AN/A$0.00 millionN/A8/6/2026Q2 2026CRMDCorMedix$0.26N/AN/AN/A$96.04 millionN/A8/6/2026Q2 2026TECXTectonic Therapeutic-$1.3488N/AN/AN/AN/AN/A5/14/2026Q1 2026CRMDCorMedix$0.35$0.43+$0.08$0.43$104.96 million$127.43 million5/13/2026Q1 2026ALLOAllogene Therapeutics-$0.19-$0.18+$0.01-$0.18$0.00 millionN/A5/13/2026Q1 2026EQEquillium-$0.04-$0.06-$0.02-$0.06N/AN/A5/7/2026Q1 2026TECXTectonic Therapeutic-$1.16-$1.34-$0.18-$1.34N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthALLOAllogene TherapeuticsN/AN/AN/AN/AN/ACRMDCorMedixN/AN/AN/AN/AN/AEQEquilliumN/AN/AN/AN/AN/ATECXTectonic TherapeuticN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALLOAllogene TherapeuticsN/A9.659.65CRMDCorMedix0.332.972.74EQEquilliumN/A18.6218.62TECXTectonic TherapeuticN/A18.5118.51Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALLOAllogene Therapeutics83.63%CRMDCorMedix34.18%EQEquillium27.05%TECXTectonic Therapeutic62.63%Insider OwnershipCompanyInsider OwnershipALLOAllogene Therapeutics13.20%CRMDCorMedix3.50%EQEquillium17.84%TECXTectonic Therapeutic39.80%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableALLOAllogene Therapeutics310345.16 million299.60 millionOptionableCRMDCorMedix3078.45 million75.71 millionOptionableEQEquillium4063.23 million51.95 millionNot OptionableTECXTectonic Therapeutic12018.87 million11.36 millionN/AEQ, TECX, ALLO, and CRMD HeadlinesRecent News About These CompaniesTectonic Therapeutic (NASDAQ:TECX) Stock Rating Lowered by Zacks ResearchJuly 22 at 5:41 AM | marketbeat.comTectonic Therapeutic (NASDAQ:TECX) Trading Up 6.3% - Time to Buy?July 17, 2026 | marketbeat.comTectonic Therapeutic (NASDAQ:TECX) Stock Price Down 4.4% - Time to Sell?July 15, 2026 | marketbeat.comTectonic Therapeutic, Inc. (NASDAQ:TECX) Given Consensus Rating of "Buy" by BrokeragesJuly 13, 2026 | marketbeat.comTectonic Therapeutic IncJuly 2, 2026 | edition.cnn.comWhy Tectonic Therapeutic, Inc.’s (TECX) Stock Is Up 5.05%June 30, 2026 | aaii.comATectonic Therapeutic Completes Enrollment in Key TX45 TrialJune 10, 2026 | tipranks.comTectonic Therapeutic Completes Enrollment in TX45 APEX Phase 2 Clinical Trial in PH-HFpEF PatientsJune 10, 2026 | globenewswire.comTectonic Therapeutic Inc TECXMay 31, 2026 | morningstar.comMRaymond James upgrades Tectonic Therapeutic (TECX)May 27, 2026 | msn.comTectonic Therapeutics: Currently In A Catalyst VacuumMay 19, 2026 | seekingalpha.comLifeSci Capital Sticks to Its Buy Rating for Tectonic Therapeutic (TECX)May 17, 2026 | theglobeandmail.comAnalysts Are Bullish on These Healthcare Stocks: Tectonic Therapeutic (TECX), Celldex (CLDX)May 11, 2026 | theglobeandmail.comTectonic Therapeutic Announces First Quarter 2026 Financial Results and Recent Business HighlightsMay 7, 2026 | globenewswire.comTectonic Therapeutic (NASDAQ:TECX) Insider Marcella Ruddy Sells 1,065 SharesMay 7, 2026 | insidertrades.comTectonic Therapeutic Appoints Jessica Chutter to Board of DirectorsApril 23, 2026 | globenewswire.comStifel initiates coverage of Tectonic Therapeutic (TECX) with buy recommendationApril 16, 2026 | msn.comTectonic Therapeutic: A $1B+ Opportunity Hinges On Upcoming Phase 2April 16, 2026 | seekingalpha.comInsider Selling: Tectonic Therapeutic (NASDAQ:TECX) Insider Sells 1,000 Shares of StockApril 4, 2026 | insidertrades.comTectonic Therapeutic, Inc. $TECX Shares Sold by Ally Bridge Group NY LLCMarch 15, 2026 | defenseworld.netDInsider Selling: Tectonic Therapeutic (NASDAQ:TECX) Insider Sells 6,262 Shares of StockMarch 10, 2026 | insidertrades.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesBroadcom's $30 Billion Apple Deal: This Chip Giant Is About More than Just AIBy Leo Miller | July 10, 2026Rocket Lab Defies Gravity With $8B BuyoutBy Jeffrey Neal Johnson | June 30, 2026AST SpaceMobile Stock Sinks as SpaceX Fallout Rattles Space SectorBy Jessica Mitacek | July 17, 2026Could Truth API Become Trump Media’s First Meaningful Revenue Driver?By Jeffrey Neal Johnson | July 22, 2026The Market Just Got Shaken—These 3 ETFs May Come Out StrongerBy Ryan Hasson | July 8, 2026EQ, TECX, ALLO, and CRMD Company DescriptionsAllogene Therapeutics NASDAQ:ALLO$1.74 -0.08 (-4.40%) Closing price 07/24/2026 04:00 PM EasternExtended Trading$1.74 0.00 (-0.29%) As of 07/24/2026 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL). The company also develops cemacabtagene ansegedleucel, an engineered allogeneic CAR T cell product candidate that targets CD19 for the treatment of large B-cell lymphoma; and is in Phase 1b clinical trial for the treatment of chronic lymphocytic leukemia. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase 1 clinical trial for treating R/R multiple myeloma; ALLO-605, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; ALLO-316, an allogeneic CAR T cell product candidate that is in Phase 1 clinical trial for the treatment of advanced or metastatic RCC; ALLO-329 for the treatment of certain autoimmune diseases; DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors; and Claudin 18.2 for the treatment of gastric and pancreatic cancer. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates; and a strategic partnership with Foresight Diagnostics to develop MRD-based In-Vitro Diagnostic for use in ALPHA3. The company was incorporated in 2017 and is headquartered in South San Francisco, California.CorMedix NASDAQ:CRMD$7.87 -0.18 (-2.24%) Closing price 07/24/2026 04:00 PM EasternExtended Trading$7.87 0.00 (0.00%) As of 07/24/2026 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. CorMedix Inc. was incorporated in 2006 and is based in Berkeley Heights, New Jersey.Equillium NASDAQ:EQ$2.49 -0.20 (-7.43%) Closing price 07/24/2026 04:00 PM EasternExtended Trading$2.50 +0.00 (+0.20%) As of 07/24/2026 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Equillium, Inc., a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. The company's lead product candidate is itolizumab (EQ001), a first-in-class monoclonal antibody that targets the immune checkpoint receptor CD6, which is in Phase III clinical trials for the treatment of acute graft-versus-host disease; completed Phase I clinical trial for the treatment of ulcerative colitis; and Phase I clinical trial for the treatment of lupus nephritis. It also develops EQ101 completed phase 1/2 for treatment of cutaneous T cell lymphoma and alopecia areata; and EQ302 to treat gastrointestinal indications. In addition, it serves dermatology, gastroenterology, rheumatology, hematology, transplant science, oncology, and pulmonology area. The company was formerly known as Attenuate Biopharmaceuticals, Inc. and changed its name to Equillium, Inc. in May 2017. Equillium, Inc. was incorporated in 2017 and is headquartered in La Jolla, California.Tectonic Therapeutic NASDAQ:TECX$30.37 -1.24 (-3.92%) Closing price 07/24/2026 04:00 PM EasternExtended Trading$30.36 -0.01 (-0.03%) As of 07/24/2026 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Tectonic Therapeutic, Inc. engages in discovery and development of therapeutic proteins & antibodies. The company was founded by Timothy A. Springer and Andrew Kruse in 2019 and is headquartered in Watertown, MA. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 07/20- 07/24 AMD and Cerbras Create A New Blueprint For Hardware Intel Earnings Reveal Whether the Chip Selloff Created a Buy CrowdStrike’s Cerebras Deal Puts Its AI Security Strategy to the Test Freeport McMoRan Post-Earnings: Why Good Enough May Finally Be Good Enough Tesla Just Delivered Record Sales—So Why Did the Stock Sell Off? Plugging In: How Kinder Morgan Powers Up Profits TSMC’s Price Hikes Could Show Which AI Chip Stocks Have Real Pricing Power Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
